Is Ardent Health, Inc. overvalued or undervalued?

As of 17 October 2025, Ardent Health, Inc. has moved from an attractive to an expensive valuation grade, indicating a shift towards being overvalued. The company is currently considered overvalued based on its recent performance and valuation ratios. The price-to-earnings (P/E) ratio is not available, but the company’s current price of $14.63 is significantly higher than its 52-week low of $10.10, suggesting potential overvaluation. In comparison to the S&P 500, Ardent Health's stock has underperformed significantly over the past year, with a return of -24.97% compared to the S&P 500's 14.08%. This stark contrast reinforces the notion that the stock may be overvalued given its poor performance relative to the broader market.